Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
about
EQ-5D Health Utility Scores: Data from a Comprehensive Canadian Cancer Centre.Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesotheliomaMapping Functions in Health-Related Quality of Life: Mapping from Two Cancer-Specific Health-Related Quality-of-Life Instruments to EQ-5D-3L.Cost-Effectiveness of Autologous Stem Cell Treatment as Compared to Conventional Chemotherapy for Treatment of Multiple Myeloma in India.Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer.Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma.Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia.Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States.Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.The potential for a generally applicable mapping model between QLQ-C30 and SF-6D in patients with different cancers: a comparison of regression-based methods.The Development of Quality of Life Questionnaire for Indonesian Breast Cancer Patients: INA-BCHRQoL
P2860
Q31124402-498648FF-6339-4D6E-8A8D-FD0A7AC597E2Q35047438-880E6B08-408E-4C16-A410-09357DFAF008Q36070909-972E0829-D67C-4A49-99F1-2B9717FB5674Q38757989-0BE808BD-9119-4348-9E0A-BC3F3AFF7E22Q39346865-36191900-CEFA-4E7C-A360-44EDF594E285Q39737036-B5348307-86D8-4423-9679-2C3FBE972243Q42940568-CF63BA27-E9E8-4AE1-AD50-6894E99ED8EAQ47673299-00D104E6-3B4F-484D-8B2B-06E15F175D30Q47804400-656BC20C-8496-446A-B48D-754858A02054Q47960020-256B33A0-0410-44DF-A9D9-FCBC8D337403Q48060040-6FCF4484-E3D0-4049-88AA-3CCA92435EB1Q55709549-C97FACDD-C72B-4CEF-B9CE-6871FA36EE54
P2860
Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
@ast
Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
@en
Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
@nl
type
label
Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
@ast
Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
@en
Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
@nl
prefLabel
Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
@ast
Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
@en
Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
@nl
P2093
P2860
P356
P1476
Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
@en
P2093
Cathy D Williams
Charalampia Kyriakou
Faith E Davies
Irina Proskorovsky
Jack Ishak
Karin Jordan
Philip Lewis
P2860
P2888
P356
10.1186/1477-7525-12-35
P577
2014-03-11T00:00:00Z
P5875
P6179
1048346827